Covid-19 roundup: As­traZeneca builds $261M deal with US CD­MO play­er for bulk Covid-19 vac­cine sup­ply; Cor­po­rate in­sid­ers reel­ing in over $1B+

Less than 2 months af­ter BAR­DA spear­head­ed US ef­forts to en­sure a large sup­ply of vac­cine to fight Covid-19 with a $628 mil­lion al­liance with Emer­gent BioSo­lu­tions, As­traZeneca has stepped up with a new, $174 mil­lion add-on con­tract for its CD­MO op­er­a­tion to pro­duce their Ox­ford vac­cine at scale in Emer­gent’s Bal­ti­more fa­cil­i­ty.

As­traZeneca promised it could de­liv­er 2 bil­lion dos­es of their vac­cine to the world next year, mak­ing it one of the lead­ing play­ers in the dri­ve to in­oc­u­late the world against Covid-19. This new con­tract de­vel­op­ment and com­mer­cial­iza­tion pact builds on their ini­tial $87 mil­lion con­tract re­gard­ing AZD1222, which they signed in June.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER